在阿尔茨海默氏病研究中心跨种族和民族的参考来源
Carol K Chan1, Kathleen A Lane2, Sujuan Gao2
1Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Journal of Alzheimer's disease : JAD
|October 4, 2024
概括
代表性不足的群体在阿尔茨海默病研究中获得专业转诊的几率较低. 了解转诊差异对于改善痴呆症研究中的多样性至关重要.
科学领域:
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
- 临床研究 临床研究
背景情况:
- 在阿尔茨海默病和相关痴呆症 (ADRD) 研究中,代表性不足的群体 (URG) 的入学率低,阻碍了研究进展.
- 识别参与障碍对于增加临床试验多样性的必要.
- 推来源是影响参与者招聘的关键因素.
研究的目的:
- 在阿尔茨海默氏病中心 (ADCs) 研究的参与者中,比较跨种族和民族的转介来源.
- 调查不同种族和种族群体如何被指向ADRD研究的潜在差异.
主要方法:
- 国家阿尔茨海默氏症协调中心统一数据集的二次分析,包括46个ADRC的48,330名参与者.
- 混合效应的物流回归模型被用来比较专业与非专业的推来源,按种族和种族.
- 分析根据年龄,性别,教育,访问年份,临床痴呆症评分表和研究地点进行了调整.
主要成果:
- 与非西班牙裔白人参与者相比,非西班牙裔黑人和亚裔参与者获得专业推的几率明显较低.
- 调整后的赔率比率表明,黑人 (OR=0.61) 和亚裔 (OR=0.65) 个体的专业推可能性降低.
- 在接受MRI扫描的参与者中,没有观察到推来源的显著差异.
结论:
- 在ADRD研究中,代表性不足的种族和种族群体的专业推模式存在差异.
- 需要进一步的研究来确定导致这些转介差异的系统和结构因素.
- 解决这些差异对于增强不同人群在痴呆症研究中的招聘和参与至关重要.
更多相关视频
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.3K
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.2K
相关概念视频
02:16Surveys
14.7K
Often, psychologists develop surveys as a means of gathering data. Surveys are lists of questions to be answered by research participants, and can be delivered as paper-and-pencil questionnaires, administered electronically, or conducted verbally. Generally, the survey itself can be completed in a short time, and the ease of administering a survey makes it easy to collect data from a large number of people.
14.7K
02:55Stereotypes, Prejudice, and Discrimination
90.1K
Humans are very diverse and although we share many similarities, we also have many differences. The social groups we belong to help form our identities (Tajfel, 1974). These differences may be difficult for some people to reconcile, which may lead to prejudice toward people who are different. Prejudice is a negative attitude and feeling toward an individual based solely on one’s membership in a particular social group (Allport, 1954; Brown, 2010). Prejudice is common against people who...
90.1K
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451